Early alveolar epithelial cell necrosis is a potential driver of COVID-19-induced acute respiratory distress syndrome
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
-
-
SciScore for 10.1101/2022.01.23.22269723: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: The study protocol was approved by the Yokohama City University Hospital institutional review board (B200700100).
Consent: The requirement for informed consent was waived due to the observational nature of the study.
IACUC: Animal experiments: All animal experimental protocols were approved by Yokohama City University Animal Research Committee.Sex as a biological variable Male specific-pathogen-free C57/BL6J mice aged 8–10 weeks were used. Randomization Twelve animals were randomly allocated to one of the following three groups (n = 4 per group): control, mild COVID-19, and severe COVID-19. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources To … SciScore for 10.1101/2022.01.23.22269723: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: The study protocol was approved by the Yokohama City University Hospital institutional review board (B200700100).
Consent: The requirement for informed consent was waived due to the observational nature of the study.
IACUC: Animal experiments: All animal experimental protocols were approved by Yokohama City University Animal Research Committee.Sex as a biological variable Male specific-pathogen-free C57/BL6J mice aged 8–10 weeks were used. Randomization Twelve animals were randomly allocated to one of the following three groups (n = 4 per group): control, mild COVID-19, and severe COVID-19. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources To evaluate effects of anti-HMGB-1 neutralizing antibodies in severe COVID-19 animal model, six animals were randomly placed in either anti-HMGB-1 antibody or isotype control groups (n = 3 for each). anti-HMGB-1 neutralizingsuggested: Noneanti-HMGB-1suggested: NoneThen, 100 μg anti-HMGB-1 neutralizing or isotype control antibodies dissolved in 100 μL PBS were intravenously administered via the tail vein 4 h after intratracheal instillation. isotype control antibodies dissolved in 100 μL PBSsuggested: NoneLung tissue sections were stained with anti-phospho-MLKL and anti- GSDMD n-terminal antibodies. anti-phospho-MLKLsuggested: Noneanti- GSDMDsuggested: NoneExperimental Models: Organisms/Strains Sentences Resources Male specific-pathogen-free C57/BL6J mice aged 8–10 weeks were used. C57/BL6Jsuggested: NoneSoftware and Algorithms Sentences Resources Statistical analyses: Statistical analyses were performed using Prism 9 (GraphPad Software, La Jolla, CA). GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:This study has some limitations. First, only patients admitted to a single center were included in the analysis due to the limited availability of clinical samples. Further studies that use samples from multiple centers several countries are warranted. Second, our animal model was created by exposing mice to components of SARS-CoV-2, and not an infectious strain of SARS-CoV-2. Despite this, the observation of a COVID-19- like pathology supports the use of our animal model. Importantly, use of a non- infectious model is convenient for laboratories that do not specialize in infectious disease research. Third, the efficacy of inhibiting a single DAMP, HMGB-1, was evaluated. Several DAMPs are released from necrotic cells; therefore, future studies that investigate whether other DAMP are promising therapeutic targets for COVID-19 are warranted.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-